Differentiated expression of somatostatin receptor subtypes in experimental models and clinical neuroblastoma

Pediatric Blood and Cancer

Volumn 56, Issue 4, 2011, Pages 584-589

  Georgantzi, Kleopatra ^a   Tsolakis, Apostolos V ^a   Stridsberg, Mats ^a   Jakobson, Åke ^b   Christofferson, Rolf ^a   Janson, Eva Tiensuu ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cell lines; Neuroblastoma; Somatostatin analogs; Somatostatin receptors

Indexed keywords

ANTINEOPLASTIC AGENT; CHROMOGRANIN A; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; SOMATOSTATIN RECEPTOR 5;

ANIMAL EXPERIMENT; ANIMAL MODEL; BIOPSY; CANCER CHEMOTHERAPY; CANCER GRAFT; CELL CULTURE; CELL LINE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LETTER; MOUSE; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL;

ADOLESCENT; ANIMALS; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; CHROMOGRANIN A; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; MICE; MICE, NUDE; NEUROBLASTOMA; RECEPTORS, SOMATOSTATIN;

EID: 79551653330     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22913     Document Type: Letter

References (37)

1. Stiller CA, Parkin DM. International variations in the incidence of neuroblastoma. Int J Cancer 1992;52:538-543.
2. Brodeur GM, Maris JM, Yamashiro DJ, et al. Biology and genetics of human neuroblastomas. J Pediatr Hematol Oncol 1997;19:93-101.
3. Gestblom C, Hoehner JC, Hedborg F, et al. In vivo spontaneous neuronal to neuroendocrine lineage conversion in a subset of neuroblastomas. Am J Pathol 1997;150:107-117.
4. Maris JM, Hogarty MD, Bagatell R, et al. Neuroblastoma. Lancet 2007;369:2106-2120.
5. Patel YC. Somatostatin F and its receptor family. Front Neuroendocrinol 1999;20:157-198.
6. Reichlin S. Somatostatin. N Engl J Med 1983;309:1495-1501.
7. Brazeau P, Vale W, Burgus R, et al. Isolation of somatostatin (a somatotropin release inhibiting factor) of ovine hypothalamic origin. Can J Biochem 1974;52:1067-1072.
8. Reubi JC, Kvols LK, Waser B, et al. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 1990;50:5969-5977.
9. Reubi JC, Laissue J, Krenning E, et al. Somatostatin receptors in human cancer: Incidence characteristics, functional correlates and clinical implications. J Steroid Biochem Mol Biol 1992;43:27-35.
10. Foekens JA, Portengen H, van Putten WL, et al. Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res 1989;49 (24 Pt 1): 7002-7009.
11. Moertel CL, Reubi JC, Scheithauer BS, et al. Expression of somatostatin receptors in childhood neuroblastoma. Am J Clin Pathol 1994;102:752-756.
12. 3]Octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma. J Nucl Med 2006;47:1599-1606.
13. 3]Octreotate: Toxicity, efficacy and survival. J Clin Oncol 2008;26:2124-2130.
14. Backman U, Svensson A, Christofferson R. Importance of vascular endothelial growth factor A in the progression of experimental neuroblastoma. Angiogenesis 2002;5:267-274.
15. Portela-Gomes GM, Stridsberg M, Grimelius L, et al. Expression of the five different somatostatin receptor subtypes in endocrine cells of the pancreas. Appl Immunohistochem Mol Morphol 2000;8:126-132.
16. Stridsberg M, Hellman U, Wilander E, et al. Fragments of chromogranin A are present in the urine of patients with carcinoid tumours: Development of a specific radioimmunoassay for chromogranin A and its fragments. J Endocrinol 1993;139:329-337.
17. Kogner P, Borgstrom P, Bjellerup P, et al. Somatostatin in neuroblastoma and ganglioneuroma. Eur J Cancer 1997;33:2084-2089.
18. Qualman SJ, O'Dorisio MS, Fleshman DJ, et al. Neuroblastoma. Correlation of neuropeptide expression in tumor tissue with other prognostic factors. Cancer 1992;70:2005-2012.
19. O'Dorisio MS, Chen F, O'Dorisio TM, et al. Characterization of somatostatin receptors on human neuroblastoma tumors. Cell Growth Differ 1994;5:1-8.
20. Maggi M, Baldi E, Finetti G, et al. Identification, characterization, and biological activity of somatostatin receptors in human neuroblastoma cell lines. Cancer Res 1994;54:124-133.
21. Freeman SR, Mitra S, Malik TH, et al. Expression of somatostatin receptors in arginine vasopressin hormone-secreting olfactory neuroblastoma-Report of two cases. Rhinology 2005;43:61-65.
22. Kwekkeboom DJ, Krenning EP. Somatostatin receptor imaging. Semin Nucl Med 2002;32:84-91.
23. Schilling FH, Bihl H, Jacobsson H, et al. Combined (111)In-pentetreotide scintigraphy and (123)I-mIBG scintigraphy in neuroblastoma provides prognostic information. Med Pediatr Oncol 2000;35:688-691.
24. Limouris GS, Giannakopoulos V, Stavraka A, et al. Comparison of In-111 pentetreotide, Tc-99m (V)DMSA and I-123 mlBG scintimaging in neural crest tumors. Anticancer Res 1997;17:1589-1592.
25. Albers AR, O'Dorisio MS, Balster DA, et al. Somatostatin receptor gene expression in neuroblastoma. Regul Pept 2000;88:61-73.
26. Raggi CC, Maggi M, Renzi D, et al. Quantitative determination of sst2 gene expression in neuroblastoma tumor predicts patient outcome. J Clin Endocrinol Metab 2000;85:3866-3873.
27. Sestini R, Orlando C, Peri A, et al. Quantitation of somatostatin receptor type 2 gene expression in neuroblastoma cell lines and primary tumors using competitive reverse transcription-polymerase chain reaction. Clin Cancer Res 1996;2:1757-1765.
28. Schilling FH, Ambros PF, Bihl H, et al. Absence of somatostatin receptor expression in vivo is correlated to di- or tetraploid 1p36-deleted neuroblastomas. Med Pediatr Oncol 2001;36:56-60.
29. O'Dorisio MS, Khanna G, Bushnell D. Combining anatomic and molecularly targeted imaging in the diagnosis and surveillance of embryonal tumors of the nervous and endocrine systems in children. Cancer Metastasis Rev 2008;27:665-677.
30. Korner M, Eltschinger V, Waser B, et al. Value of immunohistochemistry for somatostatin receptor subtype sst2A in cancer tissues: Lessons from the comparison of anti-sst2A antibodies with somatostatin receptor autoradiography. Am J Surg Pathol 2005;29:1642-1651.
31. Geatti O, Shapiro B, Sisson JC, et al. Iodine-131 metaiodobenzylguanidine scintigraphy for the location of neuroblastoma: Preliminary experience in ten cases. J Nucl Med 1985;26:736-742.
32. Janson ET, Westlin JE, Eriksson B, et al. [111In-DTPA-D-Phe1]octreotide scintigraphy in patients with carcinoid tumours: The predictive value for somatostatin analogue treatment. Eur J Endocrinol 1994;131:577-581.
33. Volante M, Brizzi MP, Faggiano A, et al. Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: A proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 2007;20:1172-1182.
34. Janson ET. Treatment of neuroendocrine tumors with somatostatin analogs. Pituitary 2006;9:249-256.
35. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group. J Clin Oncol 2009;27:4656-4663.
36. 3]octreotate. Eur J Nucl Med Mol Imaging 2003;30:417-422.
37. Weckbecker G, Briner U, Lewis I, et al. SO M230: A new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin- like growth factor-I axis in rats, primates, and dogs. Endocrinology 2002;143:4123-4130.